Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody
Alexander J. Rossi, Tahsin M. Khan, Areeba Saif, Thomas U. Marron, Jonathan M. Hernandez
Topics & Concepts
NivolumabMedicineHepatocellular carcinomaSurgical oncologyAntibodyOncologyImmunotherapyNeoadjuvant therapyCarcinomaCancer researchInternal medicineImmunologyCancerBreast cancerHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersLiver physiology and pathology